NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $5.33 +0.02 (+0.38%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amylyx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$5.14▼$5.6650-Day Range$2.09▼$5.3352-Week Range$1.58▼$19.95Volume1.90 million shsAverage Volume2.05 million shsMarket Capitalization$362.47 millionP/E RatioN/ADividend YieldN/APrice Target$14.57Consensus RatingHold Company OverviewAmylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More… top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Amylyx Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks84th Percentile Overall ScoreAMLX MarketRank™: Amylyx Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 205th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.27) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.45% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently decreased by 21.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth.Read more about Amylyx Pharmaceuticals' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.45% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently decreased by 21.09%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.88 News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Amylyx Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest19 people have searched for AMLX on MarketBeat in the last 30 days. This is an increase of 850% compared to the previous 30 days.MarketBeat Follows9 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have bought 234.24% more of their company's stock than they have sold. Specifically, they have bought $321,200.00 in company stock and sold $96,099.00 in company stock.Percentage Held by Insiders11.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMLX Stock News HeadlinesCamille L. Bedrosian Sells 11,442 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) StockOctober 3, 2024 | insidertrades.comBank of America Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)October 29 at 3:42 AM | markets.businessinsider.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 29, 2024 | Porter & Company (Ad)Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals IncOctober 25, 2024 | finance.yahoo.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to "Buy" at Bank of AmericaOctober 25, 2024 | americanbankingnews.comNeutral Stance on Amylyx Pharmaceuticals Amid Promising Data and UncertaintiesOctober 23, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX)October 21, 2024 | americanbankingnews.comWhy Amylyx Pharmaceuticals Stock Was So Healthy This WeekOctober 18, 2024 | fool.comSee More Headlines AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $14.72 at the start of the year. Since then, AMLX shares have decreased by 63.8% and is now trading at $5.33. View the best growth stocks for 2024 here. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.35. The firm had revenue of ($1.02) million for the quarter, compared to analysts' expectations of $18.83 million. Amylyx Pharmaceuticals had a negative trailing twelve-month return on equity of 15.51% and a negative net margin of 17.86%. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Amylyx Pharmaceuticals' top institutional investors include abrdn plc (2.90%), Hennion & Walsh Asset Management Inc. (0.17%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Morningside Venture Investment, Justin B Klee, Joshua B Cohen, Global Investors Lp Viking, George M Milne Jr, Patrick D Yeramian, Gina Mazzariello and Daphne Quimi. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amylyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/08/2024Today10/28/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$14.57 High Stock Price Target$37.00 Low Stock Price Target$3.00 Potential Upside/Downside+173.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$49.27 million Net Margins-17.86% Pretax Margin-54.35% Return on Equity-15.51% Return on Assets-12.86% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.66 Sales & Book Value Annual Sales$298.76 million Price / Sales1.21 Cash Flow$0.94 per share Price / Cash Flow5.66 Book Value$6.42 per share Price / Book0.83Miscellaneous Outstanding Shares68,006,000Free Float60,116,000Market Cap$362.47 million OptionableOptionable Beta-0.55 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:AMLX) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.